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a b s t r a c t
Little is known about the importance of the hepatitis C virus (HCV) NS3 protease in acute hepatitis C. In
this prospective study, 82 consecutive patients with acute hepatitis C and human immunodeﬁciency
virus (HIV) coinfection were enrolled. Individuals were infected with highly related HCV strains and the
baseline NS3 quasispecies diversity and complexity was higher compared to a chronic hepatitis C control
group (Po0.0001). Both parameters were comparable in patients with spontaneous clearance (n¼6)
versus treatment-induced SVR (n¼5) or development of chronic hepatitis C (n¼9). Longitudinal NS3
quasispecies kinetics showed a trend to a decreasing diversity and complexity (Po0.05) within 4 weeks
in patients with spontaneous clearance compared to the other groups. The innate immune signalling
protein CARDIF was cleaved to a similar extent independent of the outcome. Together with a more
pronounced viral load decline (Po0.05), an early decreasing NS3 quasispecies evolution indicates
spontaneous clearance of acute hepatitis C.
& 2015 Elsevier Inc. All rights reserved.
Introduction
An acute HCV infection develops several weeks after HCV
exposure and in the majority of cases is not associated with
speciﬁc signs of liver disease. Approximately 25% of HCV mono-
infected patients spontaneously clear the infection while the
majority progress to chronic hepatitis C deﬁned as the persistence
of HCV-RNA beyond 6 months after infection (Grebely et al., 2011).
While before detection of the virus in 1989 the most frequent
transmission route was by blood transfusion currently in indus-
trialized countries the majority of new infections occur in patients
with i.v. (intravenous) drug abuse and men who have sex with
men (MSM). Especially in the last years several outbreaks of
sexually transmitted acute hepatitis C infections in HIV-positive
MSM have been reported (Danta et al., 2007; Ingiliz et al., 2014;
van de Laar et al., 2009). As the identiﬁcation of patients with a
high chance for a spontaneous clearance is of interest, several
studies identiﬁed host factors, like IL28B genotype (Grebely et al.,
2014; Liu et al., 2012; Thomas et al., 2009), HLA genotypes (Kim
et al., 2011; Neumann-Haefelin et al., 2011), combinations of both
(Fitzmaurice et al., 2015), interferon (IFN)-lambda 4 gene varia-
tions (Aka et al., 2014; Terczyńska-Dyla et al., 2014) as well as
HCV-speciﬁc T-cell and neutralizing antibody responses (Bowen
and Walker, 2005; Rehermann, 2009) in association with the
outcome of acute hepatitis C. Viral factors, as the HCV genotype
(GT) (Grebely et al., 2014), the initial HCV viral load (Liu et al.,
2012) and changes within the hypervariable region (HVR) 1 qua-
sispecies probably also contribute to a spontaneous clearance
(Farci et al., 2000; Laskus et al., 2004; Liu et al., 2012; Ray et al.,
1999; Thomson et al., 2011). The HCV quasispecies consisting of a
population of divergent but closely related viruses (Martell et al.,
1992) probably allows HCV to evade the immune response (Farci
et al., 2000). Longitudinally, an increase of substitutions within the
HVR-1 region, which is under strong selective pressure by the
immune system, are supposed to be involved in the establishment
of chronic hepatitis C (Farci et al., 2000; Thomson et al., 2011). By
contrast, another study showed higher evolutionary rates in the
HVR-1 over the time in patients with spontaneous clearance (Liu
et al., 2012).
The HCV NS3/4A protease is essential for HCV replication by
cleaving the HCV polyprotein (Moradpour et al., 2007), cleaves cellular
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proteins, like TC-PTP (T cell protein tyrosine phosphatase) and
enhances EGF (epithelial growth factor) induced signal transduction
which is essential for viral replication (Brenndorfer et al., 2009).
Furthermore, NS3/4A blocks innate immune response signal transduc-
tion pathways by cleaving TRIF (Toll-interleukin-1 receptor domain-
containing adaptor inducing IFN) (Li et al., 2005a) and CARDIF proteins
(CARD adaptor inducing IFN-ß) (also MAVS, VISA and IPS-1) (Heim,
2013; Li et al., 2005b; Meylan et al., 2005; Sklan et al., 2009), which are
important for TLR (Toll-like receptor) and RIG-I (retinoic acid inducible
gene-I) mediated signalling cascades. These pathways result in the
secretion of IFNs leading to the transcription of IFN-stimulated genes
(ISGs) mediating cellular functions limiting HCV replication (Gale and
Foy, 2005; Heim, 2013; Metz et al., 2013; Sklan et al., 2009; Thimme et
al., 2012). The inactivation of CARDIF and TRIF leads to a reduced IFN
production and impaired host defences which may promote a persis-
tent HCV infection (Bellecave et al., 2010; Sklan et al., 2009). The
expression of ISGs is critical for the outcome of pegylated (PEG)-IFN-α/
ribavirin therapy in patients with chronic hepatitis C, as in nonrespon-
ders ISGs were already upregulated before initiation of therapy
(Sarasin-Filipowicz et al., 2008). Furthermore, CARDIF cleavage was
inversely correlated with ISG expression and the cleavage extent was
higher in patients with an early virological response (Bellecave et al.,
2010). However, little is known about the role of NS3 protease in
patients with acute hepatitis C. In the present study, we analyzed the
early NS3 protease evolution, the cleavage of CARDIF as well as viral
and host factors for an elucidation of the role of the NS3 protease for
the outcome of acute hepatitis C in HIV-positive patients.
Results
Baseline characteristics of the patient cohort
For analysis of evolution and function of the HCV NS3 protease, we
enrolled 82 consecutive patients with acute hepatitis C and HIV co-
infection into a prospective study (see the Material and methods
section). The clinical characteristics of the patient cohort are shown in
Table 1. The majority of patients was infected with HCV genotype (GT)
1a (n¼66, 80.5%) and the median HCV viral load was 1.4106 IU/mL
at the time of diagnosis (baseline). In our patient cohort, we observed
an overall rate of spontaneous clearance of 13.4% (n¼11), and the
median duration between diagnosis and spontaneous clearance was
5.5 months (range 1.1–25.1 months) (Table 1). In 43 patients treat-
ment of acute hepatitis C was initiated early after a mean duration of
2.8 months (range 0.7–6.0 months) after diagnosis of acute hepatitis C
and 39 of 40 patients (97.5%) who completed the follow-up visits after
acute hepatitis C therapy, achieved a SVR and one subject had a
relapse. The majority of treated patients (93.0%, n¼40) received a
dual PEG-IFN-α/ribavirin combination therapy according to the clin-
ical recommendations (EASL, 2014). A PEG-IFN-α monotherapy was
administered to one patient, one individual was treated with PEG-
IFN-α/ribavirin/telaprevir within the context of an open label trial and
another patient obtained PEG-IFN/ribavirin/bocepevir (data not
shown). Due to different reasons acute HCV-infection of 29.3%
(n¼24) individuals was not treated within 6 months after diagnosis
leading to the development of chronic hepatitis C in those patients.
Phylogenetic analyses of NS3 proteases sequences
We constructed a neighbour-joining phylogenetic tree out of
NS3 protease nucleotide sequences from all patients at baseline
who enabled a PCR ampliﬁcation of the NS3 protease (n¼72). An
infection of single patients with several different HCV strains was
not detectable based on population based sequencing. On the basis
of the phylogenetic tree (Fig. 1) we observed highly related NS3
protease sequences. In line with deﬁnitions of a previous study
(van de Laar et al., 2009), we applied bootstrap values of 470 to
identify phylogenetic groups (see the Materials and methods
section). Using this approach, seven groups within the cohort of
GT1a-infected patients (n¼61) were identiﬁed who were infected
with similar HCV strains as well as one group consisting of
individuals infected with GT4d (n¼9) (Fig. 1). As the cohort
contains only one individual each infected with GT1b and 3a
respectively, these sequences could not be assigned to a group. The
low number of different circulating strains indicates that only a
few evolutionary closely related HCV strains are transmitted
among patients of our cohort of HIV-positive MSM.
Baseline NS3 quasispecies complexity and diversity
In order to investigate the characteristics of the NS3 quasispecies
of patients with acute hepatitis C, we performed clonal sequencing
analyses of patient samples collected at the time of diagnosis of acute
hepatitis C. We selected patients of three groups with different
outcomes: spontaneous clearance (SC) versus SVR after treatment of
acute hepatitis C (SVR) and development of a chronic hepatitis C
(cHCV). As a reference group, NS3 protease sequencing data obtained
from a previous study of patients with a long-term chronic hepatitis C
(LT cHCV) was included in our analyses (Sarrazin et al., 2007). Based
on the NS3 protease amino acid sequences, the Shannon Entropies
and Hamming Distances were calculated for each sample. At baseline,
the median Hamming Distance in patients with spontaneous clear-
ance was not signiﬁcantly different compared to individuals achieving
an treatment-induced SVR as well as compared to patients with a
development of a chronic hepatitis (median 0.0099 SC, 0.0116 SVR
aHCV, 0.0087 cHCV, P¼0.4951) (Fig. 2). Also the median Shannon
Entropy was comparable for all patients with an acute hepatitis C
irrespective of the outcome. C (median 0.0320 SC, 0.0341 SVR aHCV,
0.0260 cHCV, P¼0.5739). Furthermore, we observed no correlation of
Hamming Distances or Shannon Entropies with the HCV viral load
(data not shown). Interestingly, when we compared both parameters
in patients with acute hepatitis C versus individuals with a long-term
chronic hepatitis C, we detected signiﬁcantly higher Hamming Dis-
tances and Shannon Entropies (both Po0.0001) across all different
groups of acute hepatitis C in comparison to patients with a long-
term chronic hepatitis C. And also for each single acute hepatitis C
outcome group these differences were signiﬁcant compared to
subjects with a long-term chronic hepatitis C (Fig. 2). These results
indicate that a higher quasispecies evolution (summarizing viral
diversities calculated by Hamming Distances and viral complexities
calculated by Shannon Entropies) is occurring during acute hepatitis C
in comparison to a long-term persisting chronic HCV infection.
However, we consider that the outcome of acute hepatitis C is not
predictable by the baseline NS3 quasispecies complexity or diversity.
Longitudinal NS3 quasispecies analyses
To determine whether the NS3 quasispecies changes during the
course of acute hepatitis C in correlation with the clinical outcome,
we conducted longitudinal clonal NS3 quasispecies investigations
during the ﬁrst 24 weeks after diagnosis of acute hepatitis C and
calculated the Hamming Distances and Shannon Entropies for
patients with spontaneous clearance, SVR after treatment und
individuals with a development of a chronic hepatitis C. The values
of both parameters at baseline were subtracted from respective
parameters determined within the time intervals T1 (week 1 to
week 4), T2 (week 5 to week 9) and T3 (week 10 to week 24) after
diagnosis and the median change was calculated (Fig. 3). Most
patients with spontaneous clearance had an early and strong viral
load decline, therefore sequencing data of several patients is
available only for BL and T1. As therapy was initiated after a
median duration of 2.8 months after diagnosis, sequencing data of
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several patients with SVR after acute hepatitis C therapy is
available at BL, T1 and T2 but not at T3. For patients with
progression to chronic hepatitis C sequencing data sets from all
time points are available. Because of this, we only compared BL-T1
and BL-T2 for further analyses. When the longitudinal develop-
ment of Hamming Distances and Shannon Entropies during the
different time intervals was analyzed within each outcome group,
we detected a signiﬁcantly increasing NS3 quasispecies evolution
in patients with a development of a chronic hepatitis C between
BL-T1 (Po0.05) (Fig. 3A and B, see asterisks). All other longitudinal
quasispecies changes were not signiﬁcant within the single
groups. Next, we compared the median delta Hamming Distances
and Shannon Entropies changes for each time interval between
the different outcome groups. Early after diagnosis of acute
hepatitis C (BL-T1), patients with spontaneous clearance showed
a decrease in the median delta Hamming Distance and Shannon
Entropy compared to individuals with SVR or development of a
chronic hepatitis C, and this trend was signiﬁcant (Fig. 3A and B,
P¼0.0191 and P¼0.0152). Within the second time interval (BL-T2)
only patients with an SVR and with chronic hepatitis C could be
compared (see above). The BL-T2 comparison shows that the
median delta Hamming Distances and Shannon Entropies are in
a similar range for both groups, conﬁrming the results of the BL-T1
comparison (Fig. 3A and B, P¼0.4033 and P¼0.3121). These results
suggest, that during the early phase of acute hepatitis C, the NS3
quasispecies diversity and complexity is decreasing in patients
with spontaneous clearance in comparison to patients with a later
SVR or a development of a chronic hepatitis C.
Cleavage of CARDIF by NS3 patient proteases
To investigate the hypothesis that differences in the cleavage
activity of patient NS3 proteases for molecules of the innate
immune system may be responsible for the different outcomes
of acute hepatitis C, we transfected baseline major patient NS3/4A
isolates in cells expressing CARDIF, which is an essential protein in
mediating innate immune signalling pathways (Sklan et al., 2009).
For the analysis of the cleavage of CARDIF, patients were chosen
for which clonal NS3 protease quasispecies analyses were already
performed. We selected 5 individuals with development of chronic
hepatitis C and 4 patients who achieved a spontaneous clearance.
Patients with an SVR after treatment of acute hepatitis C were not
considered for these analyses, as therapy was initiated early before
week 24 after diagnosis (see above) and these patients may not
have had the possibility of spontaneously clearing the acute
hepatitis C. The extent of CARDIF cleavage by patient NS3/4A
isolates was determined by a transient transfection and following
Western Blot analysis (see the Materials and methods section).
Interestingly, CARDIF was cleaved by all patient NS3/4A isolates,
although full-length CARDIF was also detectable. The CARDIF
Table 1
Baseline clinical parameters of 82 patients with an acute hepatitis C and HIV coinfection.
Parameter HIV/HCV coinfected patients (n¼82)
Age (years) [median (range)] 42 (25–58)
Sex (male) [n (%)] 82 (100%)
ALT (U/L) [median (range)] 315 (29–4630)
AST (U/L) [median (range)] 157 (26–2867)
GGT (U/L) [median (range)] 194 (27–1064)
Bilirubin (U/L) [median (range)] 0.8 (0.2–10.9)
INR [median (range)] 1.0 (0.8–1.3)
Albumin (g/L) [median (range)] 58.1 (41.0–65.5)
Thrombocytes (cells/mL) [median (range)] 213 (67–348)
HCV infection
HCV viral load (IU/mL) [median (range)] 1.4106 (119–8.7107)
HCV GT 1a [n (%)] 66 (80.5%)
HCV GT 1b [n (%)] 4 (4.9%)
HCV GT 1a [n (%)] 1 (1.2%)
HCV GT 3a [n (%)] 1 (1.2%)
HCV GT 4a [n (%)] 1 (1.2%)
HCV GT 4d [n (%)] 9 (11.0%)
Estimatedb duration infection—diagnosis (months) [median (range)] 1.6 (0.1–5.0)
Duration diagnosis—initiation of therapy (months) [median (range)] 2.8 (0.7–6.0)
Duration diagnosis—spontaneous clearance (months) [median (range)] 5.5 (1.1–25.1)
Spontaneous clearance [n (% all patients)] 11 (13.4%)
Therapy of acute hepatitis Cc [n (% all patients)] 43 (52.4%)
SVR [n (% follow-up completed)] 39 (97.5%)
Relapse [n (% follow-up completed)] 1 (2.5%)
Discontinuation [n] 3
Chronic hepatitis Cd [n (% all patients)] 24 (29.3%)
Lost to follow-up [n (%)] 4 (4.9%)
IL28B CC genotype [n (%)] 41 (50.0%)
HIV infection
Patients on ART [n (%)] 64 (78.0%)
Patients with HIV o50 copies/mL [n (% treated)] 57 (89.1%)
CD4 count (cells/mL) [median (range)] 552 (204–1561)
a HCV viral load too low for a subtype determination by sequencing analyses.
b The time point of acute hepatitis C infection was documented anamnestically or if not applicable, the time point of infection was
estimated by calculating the mean date between the last time point with normal transaminases and the ﬁrst time point with a positive
HCV PCR.
c Treatment of acute hepatitis C was initiated within the ﬁrst 6 months after diagnosis.
d Chronic hepatitis C is deﬁned as positive HCV-RNA viral load 6 months after diagnosis (without consideration of the further course of
chronic hepatitis C).
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cleavage efﬁciency was independent of the later clinical outcome
of acute hepatitis C as well as from the corresponding HCV viral
load (Fig. 4). However, the expression levels of the NS3 protease
were highly variable and in some patient samples no NS3 expres-
sion was detectable at all (Fig. 4). When we tested the NS3
expression with a FLAG antibody in a respective expression
construct, we detected a similar variable NS3 expression as with
the anti NS3 antibody (data not shown). Also the transfection of
increasing DNA amounts resulted not in increased CARDIF clea-
vage levels. The NS3 expression was increased in some, but not all
patients (see Supplementary Figure). This indicates that low NS3
amounts are sufﬁcient for an efﬁcient cleavage of CARDIF. We
conclude that CARDIF cleavage by patient NS3 proteases at base-
line differs not markedly and is furthermore not able to predict the
outcome of acute hepatitis C.
Analysis of clinical and laboratory parameters in correlation with
outcome of acute hepatitis C
Several baseline laboratory parameters and genetic factors have
been described in association with the spontaneous clearance of
acute hepatitis C (Grebely et al., 2011, 2014; Liu et al., 2012;
Thomas et al., 2009; Thomson et al., 2011). Therefore, we inves-
tigated different baseline parameters in association with outcome
of acute hepatitis in patients with spontaneous clearance versus
individuals developing a chronic hepatitis C using univariate
analyses (Table 2). The liver enzyme levels and bilirubin were
elevated in patients with spontaneous clearance compared to
persons with progression to chronic hepatitis C, but these
differences were not signiﬁcant (ALT 584 versus 314 U/L,
P¼0.2240; AST 278 versus 159 U/L, P¼0.2832). The proportion
of patients with favourable IL28B genotypes was higher in patients
with spontaneous clearance versus chronic hepatitis C, but again
the differences were not signiﬁcant (rs12979860 63.6% versus
50.0%, P¼0.1493 and rs8099917, 90.9% versus 70.8%, P¼0.3875).
The IP10 levels were nearly equal in both groups and were also not
able to predict the outcome of acute hepatitis C (424 pg/mL SC
versus 439 pg/mL cHCV, P¼0.8474). The baseline HCV viral load
was lower in patients with spontaneous clearance, but this was
not signiﬁcantly different in comparison to individuals with
chronic hepatitis C (1.5106 versus 2.3106 IU/mL, P¼0.9303).
Interestingly, when we calculated the median spontaneous max-
imal HCV viral load drop within the ﬁrst 12 weeks after diagnosis
of acute hepatitis C, we observed a signiﬁcantly higher HCV viral
load decline in individuals with spontaneous clearance compared
to chronic hepatitis C (median log10 3.5 versus 1.7 IU/mL,
P¼0.0135), which might serve as helpful additional parameter in
predicting spontaneous clearance.
Discussion
Besides strong immunological T-cell and neutralizing antibody
responses, also several other host and viral factors have been
shown to be associated with spontaneous clearance (Aka et al.,
2014; Beinhardt et al., 2012; Bowen and Walker, 2005; Fitzmaurice
et al., 2015; Grebely et al., 2013, 2011, 2014; Kim et al., 2011; Liu
et al., 2012; Neumann-Haefelin et al., 2011; Rehermann, 2009;
Fig. 1. Neighbour-joining phylogenetic tree based on HCV NS3 protease sequences of HIV coinfected MSM. A bootstrap analysis with 1000 replicates was performed to
identify phylogenetic groups of HCV strains. One group consists of phylogenetically similar sequences with a bootstrap value 470 and bootstrap values 470 are indicated at
the branch nodes. As only single individuals were infected with GT1b and 3a respectively, an assignment of these sequences to phylogenetic groups was not possible.
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Terczyńska-Dyla et al., 2014; Thomas et al., 2009; Thomson et al.,
2011; van den Berg et al., 2011). Regarding the evolution of the
HCV quasispecies during acute hepatitis C, studies mainly con-
centrated on the investigation of the E2 HVR1 region (Farci et al.,
2000; Laskus et al., 2004; Liu et al., 2012; Ray et al., 1999) or on the
HVR1 region in combination with NS5B (Thomson et al., 2011). One
single report is based on the analysis of the NS3 protease evolution
at the time of diagnosis of acute hepatitis C, but without including
patients with spontaneous clearance or longitudinal samples
(Nevot et al., 2014). Here, we performed longitudinal clonal NS3
protease quasispecies analyses and investigated the cleavage of
CARDIF in correlation with the outcome of acute hepatitis C in a
HIV-coinfected cohort in order to investigate the role of the NS3
protease during acute hepatitis C.
First, we examined several clinical parameters in association with
outcome in our cohort of 82 MSM with acute hepatitis C and HIV
coinfection. The rate of spontaneous clearance was relatively low
(13.4%) compared to other studies which investigated HCV mono-
infected patients with spontaneous clearance rates of approximately
25% (Grebely et al., 2011; Sklan et al., 2009). Spontaneous clearance
rates in a similar range have been reported by other studies
investigating HIV-coinfected cohorts (Thomson et al., 2011). As multi-
speciﬁc CD4 and CD8 T-cell responses are associated with HCV
recovery, lower spontaneous clearance rates in HIV-coinfected
patients are expectable due to long-term HIV-coinfection (Low
et al., 2008). Furthermore, treatment was initiated early (median
2.8 months after diagnosis), possibly not enabling a spontaneous
clearance in some cases, as in our cohort spontaneous clearance
occurred at a median time of 5.5 months after diagnosis.
Interestingly, based on NS3 protease nucleotide sequence
analyses at the time of diagnosis we observed a close evolutionary
relationship of NS3 sequences, indicating that acute hepatitis C is
caused by a relatively small number of closely related HCV strains.
Similar observations with evidence of a large international net-
work of HCV transmission in HIV-positive MSM were obtained in
previous studies showing low evolutionary distances among HCV
isolates within a region of the NS5B gene and a clustering of these
sequences (Nevot et al., 2014; van de Laar et al., 2009). Therefore,
we assume that our patients are part of this international network.
When we clonally analyzed the NS3 proteasse quasispecies evolu-
tion at the time of diagnosis of acute hepatitis C, we detected that
the quasispecies diversities (Hamming Distances) and complex-
ities (Shannon Entropies) were in a similar range for all patients,
irrespective of the later outcome (spontaneous clearance versus
SVR after treatment versus chronic hepatitis C). Interestingly, we
observed a signiﬁcantly higher NS3 quasispecies diversity and
complexity in all patients with acute hepatitis C compared to
individuals with a long-term chronic HCV infection. This is in
contrast with the results of Nevot et al. (2014) who found at
baseline signiﬁcantly lower NS3 quasispecies heterogeneities as
well as complexities in acutely HCV infected MSM compared to
patients with a long-term chronic hepatitis C. But this study did
not analyze consecutive samples and also the investigation of
patients with spontaneous clearance was lacking, allowing no
Fig. 2. Clonal NS3 protease quasispecies analysis at baseline in patients with
different outcomes of acute hepatitis C (spontaneous clearance, SC; SVR after
treatment (SVR); development of chronic hepatitis C, cHCV; individuals with a
long-term chronic HCV infection, LT cHCV). (A) Quasispecies diversity (Hamming
Distance) and (B) quasipecies complexity (Shannon Entropy). (P values were
calculated using the Kruskall–Wallis test and were Bonferroni–Holm corrected).
Fig. 3. Longitudinal NS3 protease quasispecies evolution in correlation with out-
come determined by calculating the delta values for Hamming Distances and
Shannon Entropies. Comparison of Hamming Distances between baseline (BL) and
T1 and BL-T2 (A) as well as of Shannon Entropies between BL-T1 and BL-T2 (B),
(n.a., data not available). The signiﬁcance of differences in the longitudinal
quasispecies evolution between the groups was calculated by applying the
Jonckheere–Terpstra test for a statistical trend. To compute the signiﬁcance of
longitudinal changes within in each group the Wilcoxon-Matched pairs test was
used and signiﬁcant results (Po0.05) are marked with asterisks.
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conclusion of the inﬂuence of the quasispecies evolution on
outcome. Also other studies (Farci et al., 2000; Thomson et al.,
2011) showed a diversiﬁcation in HVR-1 in patients progressing to
chronic hepatitis C. Our conﬂicting result of a reduced HCV
quasispecies in long-term chronic hepatitis C could in principle
also be attributed to the fact that these patients were not HIV-
coinfected. Unfortunately, as an acute hepatitis C is mostly
asymptomatic and therefore not diagnosed, the establishment of
a large acute HCV-monoinfected cohort with frequent sampling
during the acute phase of infection is difﬁcult. However, several
studies investigated the HCV quasispecies evolution in patients
with chronic hepatitis C monoinfection versus HCV/HIV coinfec-
tion. A decreased NS3 and HVR quasispecies variability was found
in patients with HIV coinfection compared to HCV monoinfection
(Jabara et al., 2014; Shuhart et al., 2006). This effect appeared to be
reversed by effective ART (Shuhart et al., 2006). But other
researchers could not detect any difference in HCV quasispecies
diversity between HCV-moninfected versus HIV-coinfected indivi-
duals (Netski et al., 2008) or between HIV-coinfected patients
receiving ART or not (Winters et al., 2010). In acute hepatitis C,
comparisons between HCV monoinfected and HIV-coinfected
patients were performed only by the above mentioned study
(Nevot et al., 2014) which showed no differences in the NS3
quasispecies heterogeneity and complexity between both groups.
Although, we cannot completely rule out that the observed
differences between acute and long-term hepatitis C are
Fig. 4. Investigation of CARDIF cleavage in cells transfected with NS3/4A isolates of GT1a-infected patients in correlation with outcome by immunoblotting. (A) Analysis of
CARDIF cleavage showing full length and cleaved CARDIF protein (B) NS3 expression of the patient isolates. Beta-actin was analyzed on each immunoblot as a loading control.
Table 2
Univariate analysis of possible predictors for spontaneous clearance of acute hepatitis C.
Parameter Spontaneous clearance n¼11 Chronic hepatitis C n¼24 P-value
Age (years) [median (range)] 42 (25–53) 40 (29–58) ¼0.95821
ALT (U/L) [median (range)] 584 (113–2217) 314 (29–4630) ¼0.22401
AST (U/L) [median (range)] 278 (51–745) 159 (28–2867) ¼0.28321
GGT (U/L) [median (range)] 263 (31- 992) 252 (78–843) ¼0.42991
Bilirubin (mg/dL) [median (range)] 1.4 (0.5–3.6) 0.7 (0.3–10.9) ¼0.14391
HCV GT (1a/non1a) [n ] 9/2 22/2 ¼0.57482
HCV viral load (IU/mL) [median (range)] 1.5106 (127–6.9107) 2.3106 (119–8.7107) ¼0.93031
Max. HCV-VL log10 decline (IU/mL) [median (range)] within 12 weeks 3.5 (0.7–6.4) 1.7 (0.2–5.5) ¼0.01351
NS3 Hamming Distance [median (range)] 0.0099 (0.0041–0.0158) 0.0087 (0.0016–0.0120) ¼0.45591
NS3 Shannon Entropy [median (range)] 0.0320 (0.0121–0.0450) 0.0260 (0.0051–0.0355) ¼0.52871
IL28B—rs12979860 (CC/nonCC) [n] 7/4 (63.6%) 12/12 (50.0%) ¼0.14933
IL28B rs8099917 (TT/nonTT) [n] 10/1 (90.9%) 17/7 (70.8%) ¼0.38752
IP10 (pg/mL) [median (range)] 424 (169–911) 439 (79-1560) ¼0.84741
Thrombocytes (cells/mL) [median (range)] 211 (145–307) 218 (67–320) ¼0.84741
Albumin (g/L) [median (range)] 58 (54–61) 60 (42–66) ¼0.37221
INR [median (range)] 1.0 (0.9–1.1) 1.0 (0.8–1.3) ¼0.72091
CD4 count (cells/mL) [median (range)] 523 (312–850) 625 (204–930) ¼0.47221
Patients with HIV o50 copies/mL [n (% treated)] 9/9 (100%) 20/22 (91.3%) ¼1.00002
P values are uncorrected for multiple testing.
1 Wilcoxon–Mann–Whitney-U-test.
2 Fisher’s exact test.
3 Chi-square test.
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inﬂuenced by HIV coinfection of different ART regimens in the
acute cohort, we assume that this a rather weak effect. In our
opinion the unexpected result of a decreased quasispecies varia-
bility during chronic hepatitis C is attributable to the ability of HCV
to evade cellular immunity. Cellular immune responses during
chronic hepatitis C have an isolate-speciﬁc activity and may be
ineffective against divergent strains in the quasispecies. This could
lead to the emergence of cytotoxic T lymphocyte (CTL) epitope
variants resulting in a loss of CTL recognition which are then
selected during long-term chronic hepatitis C leading to a homo-
genization of the quasispecies (Freeman et al., 2001). Our results
show that the NS3 protease is a target of the immune system
during acute hepatitis C. Of note, we detected no selection of
speciﬁc mutations within the NS3 protease neither at baseline nor
longitudinally in association with outcome (data not shown). As
we were not able to detect signiﬁcant differences in the NS3
quasispecies diversity and complexity at the time of diagnosis of
acute hepatitis C in correlation with outcome, longitudinal sam-
ples were investigated. When T1 samples (collected within week
1 and 4 after diagnosis) were compared with baseline samples,
patients with spontaneous clearance showed a signiﬁcant trend to
decreasing Delta Hamming Distances and Shannon Entropies
compared to individuals who achieved a SVR after treatment or
developed a chronic hepatitis C. These observations are consistent
with other studies which investigated the evolution of the HVR-1
region within the E2 gene during acute hepatitis C. These studies
revealed in longitudinal samples of patients with spontaneous
clearance a decreased quasispecies evolution compared to indivi-
duals with development of a chronic hepatitis C (Farci et al., 2000;
Laskus et al., 2004; Thomson et al., 2011). Interestingly, in two of
these studies (Farci et al., 2000; Thomson et al., 2011) the baseline
Hamming Distances were also not signiﬁcantly different between
patients with spontaneous clearance compared to chronic hepati-
tis C, as shown in our study. Therefore, we assume, that a
prediction of the outcome of acute hepatitis C is probably not
possible based on the baseline NS3 quasispecies diversity and
complexity but the early evolution within week 1 and 4 after
diagnosis may be supportive to identify patients which are able to
spontaneously clear the acute hepatitis C infection. When instead
of amino acids, nucleotide sequences were used for the calculation
of Hamming Distances and Shannon Entropies, the absolute values
were slightly lower. This indicates that most nucleotide changes
result in amino acid changes, possibly reﬂecting the evolutionary
pressure on NS3 during acute hepatitis C. However, nucleotide
Shannon Entropies and Hamming Distances were also signiﬁcantly
decreasing in patients with spontaneous clearance compared to
individuals with a progression to chronic hepatitis C within the
ﬁrst 4 weeks after diagnosis (data not shown).
To investigate the function of patient NS3 proteases with
respect to the cleavage of molecules of the innate immune system,
we examined the cleavage of the CARDIF protein in cell culture.
Here, we observed that CARDIF cleavage was comparable at
baseline, irrespective of the later outcome of acute hepatitis C.
Previous studies of patients with chronic hepatitis C based on an
bacteriophage in vitro assay or liver biopsies showed individual
differences in the cleavage of CARDIF with some individuals
exerting no CARDIF cleavage activity at all (Aparicio et al., 2011;
Bellecave et al., 2010). The investigations of the CARDIF cleavage
performed by Nevot et al. (2014) were based on a bacteriophage
screen also applied by Aparicio et al. (2011) and showed that NS3
proteases from patients with acute hepatitis C exhibited a greater
efﬁciency for CARDIF cleavage in comparison to individuals with
chronic hepatitis C but the cohort contained no patients with
spontaneous clearance. Interestingly, we observed highly variable
NS3 expression proﬁles in our patients which did not correlate
with the HCV viral load. The transfection of increasing DNA
amounts did not lead to an increased CARDIF cleavage and as
CARDIF is efﬁciently cleaved also in patients with no detectable
NS3 expression, we think that already small NS3 amounts are
sufﬁcient for the cleavage.
Investigations of liver biopsies of patients with chronic hepa-
titis C revealed that cleavage of CARDIF negatively correlated with
the activation of the endogenous IFN system (Bellecave et al.,
2010). However, in liver biopsies of patients with acute hepatitis C
no CARDIF cleavage was detectable at all. As these biopsies were
obtained 2–5 months after HCV transmission, the authors state
that they were taken during a relatively late phase of acute
hepatitis C. The same study showed enhanced induction of IFN-γ
speciﬁc ISGs during acute hepatitis C compared to IFN-α ISGs
which were expressed in patients with chronic hepatitis C (Dill
et al., 2012). Altogether, a different pattern of ISGs is expressed
during acute hepatitis C and furthermore the linkage of CARDIF
cleavage with ISG-/NS3-expression and outcome of acute hepatitis
C remains to be further investigated. We can conclude that the
patient NS3 isolates of our cohort in principle are all able to cleave
CARDIF in cell culture. However, whether the signalling of the
innate immune system during the early phase of acute hepatitis C
may be impaired and whether the ability of the NS3 protease to
cleave CARDIF at all is of importance for the outcome of acute
hepatitis C remains unclear.
We also examined the inﬂuence of other clinical and laboratory
parameters in correlation with the outcome of acute hepatitis C.
Known factors in association with spontaneous clearance are
favourable IL28B genotype, female sex and HCV genotype 1
(Grebely et al., 2014; Thomas et al., 2009; van den Berg et al.,
2011), higher initial HCV viremia (Liu et al., 2012) and lower IP10
levels (Beinhardt et al., 2012; Grebely et al., 2013). Furthermore,
spontaneous clearance has been shown to be predictable by a
rapid decline in HCV RNA levels, elevated bilirubin and ALT levels
as well as high CD4 counts (Thomson et al., 2011). We also
observed in our patient cohort a tendency to correlation of
favourable IL28B genotypes and higher ALT and bilirubin levels
with spontaneous clearance, although these differences were not
signiﬁcant, which is presumably due to the relatively small patient
numbers. IP10 levels as well as the initial viral load were not able
to predict spontaneous clearance in our cohort. However, we
detected a signiﬁcantly higher maximal HCV viral load decline in
patients with spontaneous clearance in comparison to patients
with development of chronic hepatitis C within the ﬁrst 12 weeks
after diagnosis. Other researchers also found that a more than
2 log10 drop of the HCV viral load within the early phase of acute
infection is associated with spontaneous clearance (Kamal et al.,
2014; Thomson et al., 2011). Nevertheless our study is limited to
identify baseline factors in association with outcome of acute
hepatitis C, as treatment was initiated early, limiting the numbers
of untreated patients necessary for these comparisons. However,
an early onset of acute hepatitis C therapy is recommended in HIV-
coinfected patients 3 months after diagnosis at latest by the
guidelines from the European AIDS clinical society (EACS, 2014).
An additional limitation may be a clonal instead of deep sequence
analysis although the importance of minor quasispecies for the
outcome of acute hepatitis C is questionable.
In conclusion, although our study has a relative small overall
cohort size, our ﬁndings suggest a role of the early HCV quasis-
pecies evolution in determining the outcome of acute hepatitis C.
In contrast to a long-term persisting chronic hepatitis C, an acute
hepatitis C is characterized by a highly diverse and complex NS3
protease quasispecies, which is not able to predict outcome at
baseline. Functional analyses of CARDIF cleavage by patient NS3
proteases showed also no marked differences. Therefore, pathways
of the innate immune system including CARDIF may not have an
essential role in determining the outcome of acute hepatitis C. In
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summary an early and decreasing NS3 protease evolution together
with a high HCV viral load decline, as a result of an effective
immune response against HCV, are able to predict spontaneous
clearance of acute hepatitis C.
Materials and methods
Patients
In a prospective study, blood was collected from 82 consecutive
patients with an acute HCV infection and a HIV coinfection (con-
ﬁrmed by a positive HIV antibody test) at the University Hospital and
the Infectious-Disease Medical Center (Infektiologikum) in Frankfurt
am Main, Germany between 2009 and 2013. Acute hepatitis C was
diagnosed within the routine laboratory examination of HIV-infected
patients. Deﬁnition of acute hepatitis C was based on previous studies
(European A.T.N.A.H.C.I.C.P., 2011; Ingiliz et al., 2014): (1) HCV anti-
body positivity plus HCV RNA positivity and a negative HCV antibody
test within the last 12 months, (2) HCV RNA detectability and a
documented negative HCV-RNA and HCV antibody test within the last
12 months (3) HCV-RNA positivity and ALT elevation of more than
5 times of the upper limit of the normal range and normal ALT within
the last 12 months. We collected serum and EDTA blood at the time of
diagnosis of acute hepatitis C infection (baseline) and during the
following routine medical visits, serum samples were taken long-
itudinally (approximately every 4 weeks over a 6 month period).
Collection of samples was stopped after HCV RNA negativity after
starting of HCV treatment or after conﬁrmed spontaneous clearance.
Viral and biochemical laboratory parameters were documented for
each time point when serum was collected. Spontaneous clearance
was deﬁned as negative HCV RNA detected twice within an interval of
at least 12 weeks without receiving therapy and conﬁrmation
6 months after diagnosis of acute hepatitis C. Sustained virologic
response (SVR) was determined by HCV RNA negativity 12 weeks
after the end-of-treatment. Chronic hepatitis C was deﬁned as the
presence of HCV RNA 24 weeks after diagnosis without treatment.
The NS3 protease was population-based sequenced in all patient
samples at baseline which yielded in a PCR product (n¼72/82) after
performing at least 3 independent experiments. The viral load of
9 patients whose samples yielded in no PCR product was low
(o8000 IU/mL), however one patient displayed a very high viral
load and the sample was not ampliﬁable at all (median¼166 IU/mL,
range o15–3.5107). For clonal NS3 quasispecies (baseline and
longitudinally before initiation of therapy/spontaneous clearance)
and CARDIF cleavage investigations (baseline), patients with sufﬁcient
longitudinal sampling and a high enough viral load (41000 IU/mL)
were selected out of different groups (spontaneous clearance versus
SVR after acute hepatitis C therapy versus progression to chronic
hepatitis C) (see the Results section). Altogether, we performed
longitudinal clonal NS3 analyses of 6 patients with spontaneous
clearance, 5 individuals with treatment-induced clearance of acute
hepatitis C and 9 patients with chronic hepatitis C. For the investiga-
tion of the CARDIF cleavage at baseline, out of these patients,
5 individuals with progression to chronic hepatitis C and 4 individuals
with spontaneous clearance were selected. Approval of the enroll-
ment in the observational study as well as the usage of patient blood
samples for research purpose was obtained from the local ethics
committee, and written informed consent was obtained from all
patients.
HCV RNA extraction, reverse transcription and PCR
For the extraction of HCV RNA, 140 mL of serum was used (QIAamp
Viral RNA Mini-Kit, Qiagen, Hilden, Germany) and complementary DNA
(cDNA) was synthesized using SuperScript III Reverse Transcriptase
(Invitrogen) as mentioned before (Dietz et al., 2013). Nested PCRs of
NS3 protease and NS3/4A were carried out using 1/20 of cDNA or outer
PCR product respectively by applying the Expand High FidelityPLUS PCR
System (Roche Applied Science). Ampliﬁcation of the HCV GT1 NS3
protease domain for clonal quasispecies analyses was performed with
primers described previously (Lim et al., 2012). NS3 protease ampliﬁca-
tions of all genotypes started with an initial denaturation at 94 1C for
2min, followed by 35 cycles at 94 1C for 30 s, 30 s at the respective
annealing temperature and 72 1C for one minute and a ﬁnal elongation
step at 72 1C for 7min. GT3a was ampliﬁed using NS3-3a-sense,
CGGCTTGCGGAGATATTC and NS3-3a-outer-as, CCGTAGGTGGAATAGGT-
CAG in the outer PCR and NS3-3a-sense and NS3-3a-inner-as, AGACAT-
GAAGGAGCCGAAG in the inner PCR. The annealing temperature was
54 1C in the outer PCR and 52 1C in the inner PCR. For the ampliﬁ-
cation of GT4d, the outer PCR was conducted with NS3_4d_out_F, CCGC-
TGCATGCGGTGACATTC and NS3_4d_out_R, TTCCCGTTGGCGCGTGCAAG
and in the inner PCR NS3_4d_inn_F, CTTGCTCGGCCCGGCCGAC and
NS3_4d_inn_rev, GGGCACGGCAGGAGGAGTGG were applied and the
annealing temperature was 54 1C in both PCRs. For the utilization in
the CARDIF cleavage assay, GT1a NS3/4A was ampliﬁed using NS3/
4A_1a_out_F, ATGGAGACCAAGCTCATCACGTGGG and NS3/4A_1a_
out_R, AGGGCCTTCTGCTTGAACTGCTC in the outer PCR and NS3/
4A_1a_NheI_inn_F, ATGATGGCTAGCGCCACCATGGCGCCCATCACRGCG-
TACGCC andNS3/4A_1a_EcoRI_inn_R, ATGATGGAATTCTCACTAGCACTCTT
CCATCTCATCGAACTC in the inner PCR. The initial denaturation as well as
the ﬁnal elongation step were performed as described above. Both PCRs
were conducted with 40 cycles at 94 1C for 30 s, an annealing step for
30 s at 40 1C in the outer PCR and at 60 1C respectively in the inner PCR,
followed by 72 1C for 2.5min. The resulting PCR products were analyzed
for correct size on 1% agarose gels stained with ethidium bromide.
Cloning of NS3 protease domain and NS3/4A
The PCR products of the NS3 protease domain and NS3/4Awere
gel-puriﬁed using the QIAquick Gel Extraction Kit (Qiagen). The
NS3 protease PCR products were then cloned into the pSC-A-amp/
kan vector and transformed into Escherichia coli competent cells
(StrataClone PCR Cloning Kit, Agilent Technologies). The NS3/4A
PCR products were digested with NheI and EcoRI, cloned into
pcDNA3.1 (þ) vector (Invitrogen) and transformed into E. coli
competent cells. The puriﬁcation of plasmid DNA occurred by
using the GenElute HP 96-Well Plasmid Miniprep Kit (Sigma-
Aldrich) according to the manufacturer’s protocol.
NS3 protease domain and NS3/4A sequencing and phylogenetic
analysis
Population-based sequencing of the NS3 protease from patients at
baseline was performed by using the puriﬁed PCR-product and the
inner forward PCR primer. For clonal NS3 protease quasispecies
analysis an average of 32 clones were sequenced for each patient
using M13 reverse primer, CAGGAAACAGCTATGAC. The number of
analyzed clones was in accordance with other studies which inves-
tigated the HCV quasispecies evolution during acute hepatitis C (Farci
et al., 2000; Liu et al., 2012; Nevot et al., 2014; Ray et al., 1999;
Thomson et al., 2011). For usage in the CARDIF cleavage assay, at least
16 clones per patient containing NS3/4A were sequenced with the
pCMV forward primer, CGCAAATGGGCGGTAGGCGTG and the BGH
reverse primer, TAGAAGGCACAGTCGAGG to determine the major
(most frequent) clone within the NS3 protease as well as to verify
the functionality of the clones. Sanger sequencing was performed
according to the manufacturer’s protocol (Big Dye Terminator v1.1
Cycle Sequencing Kit, Applied Biosystems) on an ABI Prism 3130xl
Genetic Analyzer (Applied Biosystems). For the generation of a
phylogenetic tree, NS3 protease nucleotide sequences were aligned
and a Neighbour-joining tree was computed using the MEGA
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6 software (Tamura et al., 2013). In accordance with other studies
(Ingiliz et al., 2014; Nevot et al., 2014) a Tamura three-parameter
model with a gamma distribution and a bootstrap analysis (1000
replicates) was applied and bootstrap values 470 were deﬁned to
represent robust clusters as proposed previously (van de Laar et al.,
2009). To investigate NS3 mutations, the 543 nucleotides of the NS3
protease gene (corresponding to 181 amino acids) were aligned using
the software Mutational Surveyor (SoftGenetics, State College, PA).
Aligned amino acid sequences of each patient and time point were
analyzed for mutations in comparison to the baseline consensus
sequence. Furthermore, mean Shannon Entropies and Hamming
Distances were calculated for each patient and time point using an
in-house software computed by Eva Herrmann based on (Sarrazin
et al., 2001). Thereby, the Shannon Entropy is a measure for the
number of viral variants within the quasispecies (genetic complexity).
The Hamming Distance accounts for the frequency of mutations
within single isolates of the HCV quasispecies (genetic diversity).
NS3 sequence data of a control group of patients (n¼34) with long-
term chronic hepatitis C were obtained from a previous study
(Sarrazin et al., 2007). For longitudinal analysis of Shannon Entropies
and Hamming Distances, we calculated delta values for each patient
by subtracting the baseline values from the respective time point.
Serum samples corresponding to time point (T) 1 were collected
within weeks 1 and 4, samples corresponding to T2 were taken
within weeks 5 and 9 and samples corresponding to T3 were
collected within weeks 10 and 24 after diagnosis of acute hepatitis C.
Genotyping of IL28B single nucleotide polymorphisms
Genomic DNA of patient samples was extracted from EDTA
blood using QIAamp DNA Blood Kit (Qiagen). For SNP genotyping
of IL28B SNPs rs12979860 and rs8099917 a real-time polymerase
chain reaction was performed using a StepOnePlus instrument
(Applied Biosystems) as previously described (Susser et al., 2014).
Quantiﬁcation of IP-10 levels
IP-10 levels were measured by using 75 mL of 1:4 diluted
patient serum samples and commercially available CXCL10/IP-10
Quantikine ELISA Kit according to the manufacturer’s protocol
(R&D Systems).
CARDIF cleavage assay
U2OS cells expressing endogenous CARDIF protein were seeded at
a density of 900,000 cells per 5 cm diameter dish in DMEM complete
containing 10% FCS and 1% Pen/Strep. The following day, the medium
was changed and cells were transfected with 1.7 mg of NS3/4A-
pcDNA3.1 (þ) representing the major clone of the respective quasis-
pecies using X-tremeGENE HP DNA Transfection Reagent (Roche
Applied Science). 36 h after transfection, cells were harvested and
proteins were extracted with RIPA lysis buffer according to Bellecave
et al. (2010) containing 50 mM TrisCl pH 8.0, 150 mM NaCl, 1% NP40,
0.5% deoxcholate, 0.1% sodium dodecyl sulphate, 1 mM sodium
orthovanadate, 10 mM NaF and a cocktail of protease and phospha-
tase inhibitors (Complete Protease Inhibitor and Phosphostop, Roche
Applied Science). The protein content of samples was measured and
per sample 50 micrograms protein was separated on 10% denaturat-
ing sodium dodecyl sulphate polyacryl amide gelelectrophoresis.
Western Blot analysis occurred as described previously with murine
anti-CARDIF antibody 1:1000 in 5%milkpowder/PBS, anti-NS3 1:500
in 3%BSA/milk/PBS and anti-actin 1:6000 5%/PBS and horseradish
peroxidase-coupled secondary antibodies and Luminata Forte Wes-
tern HRP Substrate (Milipore) (Bellecave et al., 2010; Wolk et al.,
2000). Transfections and Western Blot analyses were performed in
three independent experiments.
Statistical analyses
We carried out statistical analyses of the data using the BIAS
software (BIAS for Windows, Version 10, © Epsilon 2013). Statis-
tical analyses of associations of continuous variables (for instance
Shannon Entropies, Hamming Distances, ALT, AST, HCV viral load,
IP10) with the outcome of acute hepatitis C were performed using
the Wilcoxon–Mann–Whitney-U-test (comparison of 2 groups) or
the Kruskall–Wallis test (comparison of 3 or more groups). To
analyze for a trend between different groups, we applied the
Jonckheere–Terpstra-Test. When time courses of Shannon Entro-
pies and Hamming Distances were compared within each patient
group, the Wilcoxon-Matched-Pairs test was applied. For the
analysis of dichotomic variables (single-nucleotide-polymorphism
(SNPs), HCV genotype) we used fourfold tables (Chi-square test,
Fisher’s exact test if more than 20% of expected frequencies were
less than 5). P-values of less than 0.05 were considered signiﬁcant.
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